-
2024 DDW丨Research by Jie Li / Yihui Yang Team Wins AASLD Abstract Award, Confirming Reduced Diagnostic Accuracy of Non-Invasive Tests for Fibrosis in MASLD with CHB
The Digestive Disease Week (DDW) in the United States is a premier global academic conference in the field of digestive system diseases. The 2024 DDW was successfully held in Washington, D.C., from May 18-21, attracting approximately 14,000 gastroenterologists and hepatologists. At the conference, a study titled “THE REDUCED ACCURACY OF NON-INVASIVE TESTS FOR SIGNIFICANT FIBROSIS…
-
Chairman Interview丨Professor Yimin Mao: Implementing Grassroots Drug-Induced Liver Injury Management and Promoting International Cooperation
Recently, the “8th International Forum on Drug-Induced Liver Injury (DILI) and the 9th National Academic Conference on Drug-Induced Liver Injury, along with the launch of the ‘2024 Chinese Guidelines for Grassroots Diagnosis and Management of Drug-Induced Liver Injury,'” was successfully held in beautiful Xiamen. This year’s conference focused on the management of liver injury caused…
-
Professor Donglu Zhao: Treatment of Burkitt Lymphoma | 2024 Nanjing Lymphoma Forum
The “2024 Nanjing Lymphoma Forum” was held in Nanjing from May 11-12, 2024. The conference, primarily conducted through in-person exchanges, invited renowned experts in the field of lymphoid tumors from both domestic and international arenas. Through lectures, case discussions, and other forms of interaction, the forum focused on the latest achievements and advancements in the…
-
Professor Xinlei Gong: New Advances in Systemic Therapy for Liver Cancer from Guideline Updates | 2024 CSCO Guideline Conference
Primary liver cancer is one of the leading causes of cancer death worldwide, and its treatment strategies have seen significant advancements in recent years. At the recent 2024 Chinese Society of Clinical Oncology (CSCO) Guideline Conference, Professor Xinlei Gong from Jinling Hospital, Nanjing University School of Medicine, delivered an outstanding lecture on the topic of…
-
Professor Shusen Wang: New ADC Drugs Leading the Way in Treating HER2-Low Breast Cancer | 2024 National Breast Cancer Conference
With the success of antibody-drug conjugates (ADCs) in treating HER2-low breast cancer patients, this patient group is receiving increased attention. The latest 2024 CSCO BC guidelines were released on April 12 in Beijing, featuring the first recommendations for treating HER2-low patients. “Oncology Frontier” invited Professor Shusen Wang from Sun Yat-sen University Cancer Center to discuss…
-
2024 ESMO BC丨Professor Qiang Liu: Clinical Trials and Real-World Data Complement Each Other to Provide Optimal Treatment for Breast Cancer Patients
At the 2024 ESMO BC conference, Professor Qiang Liu from Sun Yat-sen Memorial Hospital, Sun Yat-sen University, presented a report titled “From Phase III Clinical Trials to Real-World Data: Bridging the Gap Between Clinical Trials and Clinical Practice.” This report delved into the treatment advances for HER2-positive breast cancer, the differences between clinical trials and…
-
2024 ESMO BC丨Professor Hope S. Rugo: Breast Cancer Research – Lessons from the Past Will Shape the Future
t the 2024 ESMO BC conference, Professor Hope S. Rugo, the recipient of the 2024 ESMO Breast Cancer Award, reflected on the current challenges in the field of breast cancer during her speech. After working in the field of malignant hematology for nine years, Professor Hope S. Rugo’s mother was diagnosed with metastatic breast cancer,…
-
2024 ESMO BC丨Dato-Dxd’s Good Tolerability Supports Its Role in the Treatment of HR+/HER2- Breast Cancer
At the 2024 ESMO BC conference, new data from the TROPION-Breast01 study highlighted that notable adverse events were typically low-grade, manageable, and did not interfere with patients’ expected treatment.
Connecting Medical Expertise through Media